Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
2037-A DIAGNOSTIC ACCURACY OF VCTE AND 2D-SWE IN BIOPSY-PROVEN NAFLD AND PERFORMANCE OF TWO-STEP APPROACHES TO PREDICT ADVANCED FIBROSIS Madalina-Gabriela Taru 1,2 , Dan-Corneliu Leucuta 2 , Lidia Neamti 2 , Anca Maniu 3 , Vlad Taru 4 , Bobe Petrushev 3 , Ioana Rusu 3 , Cristian Tefas 2,3 , Petra Fischer 2 , Andreea-Ioana Terec 5 , Lucia Maria Procopciuc 2 , Bogdan Procopet 2 , Horia Stefanescu 3 and Monica Lupsor-Platon 2,3 , (1)Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy, (2)Luliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania, (3)Octavian Fodor Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania, (4)Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, (5)Niculae Stncioiu Heart Institute, 400001, Cluj-Napoca, Romania Background: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose significant challenges to the healthcare system, and the prediction of advanced fibrosis (F3) is a crucial aspect in their management
Do not continue testing a questionable pack simply because its advertised C rating appears high enough
Pharmacological Reviews , 75(4), 645-678
It is Health Canada-approved to help people with type 2 diabetes (T2D) manage their blood glucose levels
US$ 25.53
%20(1).png)
US$ 23.88
US$ 20.69
US$ 28.88
US$ 29.40
US$ 23.57
